Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection

AIM: To assess daclatasvir plus asunaprevir (DUAL) in treatment-naïve patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype 1b infection. METHODS: Patients were randomly assigned (3:1) to receive 24 wk of treatment with DUAL (daclatasvir 60 mg once daily and asun...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Lai, Wang, Fu-Sheng, Zhang, Ming-Xiang, Jia, Ji-Dong, Yakovlev, Alexey A, Xie, Wen, Burnevich, Eduard, Niu, Jun-Qi, Jung, Yong Jin, Jiang, Xiang-Jun, Xu, Min, Chen, Xin-Yue, Xie, Qing, Li, Jun, Hou, Jin-Lin, Tang, Hong, Dou, Xiao-Guang, Gandhi, Yash, Hu, Wen-Hua, McPhee, Fiona, Noviello, Stephanie, Treitel, Michelle, Mo, Ling, Deng, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Randomized Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871831/
https://www.ncbi.nlm.nih.gov/pubmed/29599611
http://dx.doi.org/10.3748/wjg.v24.i12.1361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871831/
https://www.ncbi.nlm.nih.gov/pubmed/29599611
http://dx.doi.org/10.3748/wjg.v24.i12.1361

Ejemplares similares